{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:44:03Z","timestamp":1790628243643,"version":"4.1.0"},"reference-count":72,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Asociaci\u00f3n Colombiana de Endocrinolog\u00eda","award":["Unrestricted educational grand, not numbered"],"award-info":[{"award-number":["Unrestricted educational grand, not numbered"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Clin Med Insights Endocrinol Diabetes"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Moderate-to-severe thyroid eye disease (TED) is a potentially vision-threatening inflammatory condition that requires timely, evidence-based medical management. Although intravenous glucocorticoids remain the mainstay of therapy, several biologic and immunosuppressive agents have emerged as potential alternatives, particularly in steroid-refractory disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To evaluate and compare the efficacy, safety, and therapeutic positioning of medical treatments for active moderate-to-severe thyroid eye disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources and Methods:<\/jats:title>\n                    <jats:p>A comprehensive search of PubMed, Embase, and the Cochrane Library was conducted through February 2025. Eligible studies included randomized controlled trials, meta-analyses, systematic reviews, observational cohorts, and selected case series evaluating pharmacological interventions for moderate-to-severe TED. Outcomes of interest were proptosis reduction, Clinical Activity Score (CAS) improvement, diplopia response, and safety\/tolerability. A semi-quantitative synthesis approach was used to integrate evidence across heterogeneous study designs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Fifty-eight studies met the inclusion criteria. Intravenous glucocorticoids (IVGCs) demonstrated the most consistent efficacy in controlling inflammatory activity, with modest effects on proptosis and favorable tolerability at cumulative doses below 8\u2009g. Among biologic therapies, teprotumumab showed the greatest magnitude of benefit across all efficacy domains but was limited by safety considerations and access constraints. Rituximab and tocilizumab demonstrated moderate efficacy, particularly in glucocorticoid-resistant cases. Mycophenolate mofetil emerged as the most reliable non-biologic immunosuppressive option. Oral glucocorticoids and several adjunctive therapies showed limited or inconsistent benefit.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This systematic review provides an integrated framework to support therapeutic decision-making in moderate-to-severe TED. Intravenous glucocorticoids remain the most consistently supported first-line therapy, while IGF-1R\u2013targeted biologic therapy offers the most comprehensive efficacy across key clinical domains in selected patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Registration:<\/jats:title>\n                    <jats:p>Not registered.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/11795514261426446","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T11:49:20Z","timestamp":1772279360000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Pharmacologic Therapies for Active Moderate-to-Severe TED: A Comprehensive Systematic Review"],"prefix":"10.1177","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2418-6159","authenticated-orcid":false,"given":"Carlos E.","family":"Builes-Monta\u00f1o","sequence":"first","affiliation":[{"name":"Hospital Pablo Tob\u00f3n Uribe and Universidad de Antioquia, Medellin, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Rom\u00e1n-Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Universidad de Antioquia, Medell\u00edn, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry M.","family":"Arenas-Quintero","sequence":"additional","affiliation":[{"name":"Universidad Tecnol\u00f3gica de Pereira, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Aristiz\u00e1bal-Henao","sequence":"additional","affiliation":[{"name":"Universidad Pontificia Bolivaraiana and Cl\u00ednica Las Am\u00e9ricas-AUNA, Medell\u00edn, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Del S.","family":"Cabarcas-Solano","sequence":"additional","affiliation":[{"name":"Universidad del Norte Universidad San Mart\u00edn, Barranquilla, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Camargo Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Hospital Universitario San Ignacio, Bogot\u00e1, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro A.","family":"Castellanos-Pinedo","sequence":"additional","affiliation":[{"name":"Hospital San Jer\u00f3nimo, Monter\u00eda, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta L.","family":"Mu\u00f1oz-Cardona","sequence":"additional","affiliation":[{"name":"Universidad de Antioquia and Universidad Pontificia Bolivariana, Medell\u00edn, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Restrepo-Erazo","sequence":"additional","affiliation":[{"name":"Universidad Santiago de Cali, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hernando","family":"Vargas-Uricoechea","sequence":"additional","affiliation":[{"name":"Universidad del Cauca, Popay\u00e1n, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda G.","family":"Mej\u00eda-L\u00f3pez","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3n Universitaria de Ciencias de la Salud and Hospital San Jos\u00e9, Bogot\u00e1, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,2,28]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14296"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.615993"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(25)00066-X"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-21-0479"},{"key":"e_1_3_3_6_2","unstructured":"Higgins JT Chandler J Cumpston J Li M Page T Welch M VA (eds) Cochrane handbook for systematic reviews of interventions version 6.5. (Updated August 2024) 2024. www.training.cochrane.org\/handbook"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2700"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0384-4"},{"key":"e_1_3_3_9_2","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JAC","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019; 366:l4898.","journal-title":"BMJ"},{"key":"e_1_3_3_10_2","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne JA","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.","journal-title":"BMJ"},{"key":"e_1_3_3_11_2","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea BJ","year":"2017","unstructured":"Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:j4008.","journal-title":"BMJ"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.18240\/ijo.2019.07.20"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/9799274"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvab048.1718"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.785757"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ16-0083"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-3919"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2006.01004.x"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1080\/01676830.2018.1553189"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03343835"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.4103\/2230-8210.152770"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-0148"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.86.8.7737"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-2389"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2020.35.e177"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.3389\/fopht.2023.1296092"},{"issue":"34","key":"e_1_3_3_27_2","article-title":"Predictive factors and treatment outcomes in intravenous glucocorticoid pulse therapy for active-moderate-to-severe thyroid eye disease: identifying the need for surgical interventions","author":"Giannakogeorgou A","year":"2024","unstructured":"Giannakogeorgou A, Bobbert T, Salchow D. Predictive factors and treatment outcomes in intravenous glucocorticoid pulse therapy for active-moderate-to-severe thyroid eye disease: identifying the need for surgical interventions. Thyroid. 2024; S1(34):A184.","journal-title":"Thyroid"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/aos.14751"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-023-02875-z"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.4414\/smw.2001.09781"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.4103\/sjopt.sjopt_176_22"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2111"},{"key":"e_1_3_3_33_2","article-title":"Randomized double-blind placebo-controlled trial of rituximab for treatment of Graves\u2019 ophthalmopathy","volume":"23","author":"Stan MN","year":"2013","unstructured":"Stan MN, Garrity JA, Thapa P, Bradley EA, Bahn RS. Randomized double-blind placebo-controlled trial of rituximab for treatment of Graves\u2019 ophthalmopathy. Thyroid. 2013;23:A13-A4.","journal-title":"Thyroid"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-3014"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2024.12.007"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13970"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2018.1453078"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000002573"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000000037"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2022.05.007"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1080\/01676830.2022.2119262"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910434"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614949"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1080\/01676830.2024.2323543"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo-2024-325527"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2023.12.001"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000002564"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000002531"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2021.10.017"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000000211"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1080\/21655979.2022.2101191"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1530\/ETJ-22-0017"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/128903"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-022-01862-y"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-024-02470-8"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-024-01545-0"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.1986.tb01016.x"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198911163212002"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.1997.7.579"},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-1105"},{"key":"e_1_3_3_61_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.1996.6.381"},{"key":"e_1_3_3_62_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.1999.9.47"},{"key":"e_1_3_3_63_2","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000002852"},{"key":"e_1_3_3_64_2","doi-asserted-by":"publisher","DOI":"10.1590\/S0004-27492006000600006"},{"key":"e_1_3_3_65_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.2008.01171.x"},{"key":"e_1_3_3_66_2","doi-asserted-by":"publisher","DOI":"10.1002\/jca.20244"},{"key":"e_1_3_3_67_2","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae526"},{"key":"e_1_3_3_68_2","doi-asserted-by":"publisher","DOI":"10.1111\/aos.15074"},{"key":"e_1_3_3_69_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2018-313697"},{"key":"e_1_3_3_70_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-0376"},{"key":"e_1_3_3_71_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2022.0251"},{"key":"e_1_3_3_72_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2025.3350"},{"key":"e_1_3_3_73_2","first-page":"101464","article-title":"A randomised, double-masked, placebo-controlled trial evaluating the efficacy and safety of teprotumumab for active thyroid eye disease in Japanese patients","volume":"55","author":"Hiromatsu Y","year":"2025","unstructured":"Hiromatsu Y, Ishikawa E, Kozaki A, et al. A randomised, double-masked, placebo-controlled trial evaluating the efficacy and safety of teprotumumab for active thyroid eye disease in Japanese patients. Lancet Reg Health West Pac. 2025;55:101464.","journal-title":"Lancet Reg Health West Pac"}],"container-title":["Clinical Medicine Insights: Endocrinology and Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11795514261426446","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/11795514261426446","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11795514261426446","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T20:00:25Z","timestamp":1777406425000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/11795514261426446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":72,"alternative-id":["10.1177\/11795514261426446"],"URL":"https:\/\/doi.org\/10.1177\/11795514261426446","relation":{},"ISSN":["1179-5514","1179-5514"],"issn-type":[{"value":"1179-5514","type":"print"},{"value":"1179-5514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"article-number":"11795514261426446"}}